TJ004309 for Ovarian Cancer

"TJ004309's safety is rated a 2 as there have been some studies conducted to verify its security, yet no clinical data demonstrating the efficacy of this drug exists."

"TJ004309 is most commonly used for the treatment of small cell lung cancer, but it has also been effective at managing malignant neoplasms, non-small cell lung carcinoma and postoperative cases."

"At present, this medical trial is not looking for patients. It was first published on November 2nd 2021 and updated lastly on the 14th of November 2022. If you seek alternate studies to join, 1997 clinical trials are currently seeking participants with gastrointestinal cancers while 352 are also enrolling individuals affected by TJ004309."

"This investigation is no longer accepting participants, according to the information posted on clinicaltrials.gov. Initially published November 2nd 2021 and last edited November 14th 2022, this study has ceased recruitment of candidates; however, there are currently 2349 other medical studies actively looking for volunteers."

"SCRI Tennessee Oncology Chattanooga was the originating site of TJ004309's clinical trial in 2008. Currently, there are 352 trials utilizing this medication actively recruiting patients with 80 studies having already been completed. Durham, North carolina is a major hub for these active trials."

"Currently, there are 352 clinical investigations of TJ004309 in motion across 74 nations and 1656 cities. Hoffmann-La Roche initiated the initial trial for this medication back in 2008 and it included 720 participants before achieving Phase 2 drug approval status. Subsequently, another 80 studies have transpired since that time."

"For this medical trial, there are 20 operating locations such as Duke Cancer Center in Durham, Illinois Cancer Specialists in Arlington Heights and Maryland Oncology Hematology in Rockville. Moreover, there are other sites available for patient participation."